The internist and vaccinations: Evidence-based recommendations

[1] Bias in the measure of the effectiveness of seasonal influenza vaccination among diabetics [J]. PRIMARY CARE DIABETES, 2016, 10 (06) : 398 - 406

[2] Comite d'orientation de la concertation citoyenne sur la vaccination, 2016, RAPP VACC

[3] Vaccination in adults with auto-immune disease and/or drug related immune deficiency: Results of the GEVACCIM Delphi survey [J]. VACCINE, 2009, 27 (10) : 1523 - 1529

[4] Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥ 19 years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012 December 31, 2015 [J]. VACCINE, 2016, 34 (50) : 6330 - 6334

[5] Haut conseil de la sante publique, 2012, AVIS REL DEL RESP EN

[6] Haut Conseil de la Sante Publique, 2016, GUID IMM POST VACC I

[7] Haut conseil de la sante publique, 2014, VACC PERS IMM ASPL R, P83

[8] Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly [J]. MEDICINE, 2016, 95 (26)

[9] Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease [J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (07) : 1047 - 1047

[10] Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS) [J]. VACCINE, 2015, 33 (36) : 4398 - 4405

[1] Bias in the measure of the effectiveness of seasonal influenza vaccination among diabetics [J]. PRIMARY CARE DIABETES, 2016, 10 (06) : 398 - 406

[2] Comite d'orientation de la concertation citoyenne sur la vaccination, 2016, RAPP VACC

[3] Vaccination in adults with auto-immune disease and/or drug related immune deficiency: Results of the GEVACCIM Delphi survey [J]. VACCINE, 2009, 27 (10) : 1523 - 1529

[4] Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥ 19 years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012 December 31, 2015 [J]. VACCINE, 2016, 34 (50) : 6330 - 6334

[5] Haut conseil de la sante publique, 2012, AVIS REL DEL RESP EN

[6] Haut Conseil de la Sante Publique, 2016, GUID IMM POST VACC I

[7] Haut conseil de la sante publique, 2014, VACC PERS IMM ASPL R, P83

[8] Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly [J]. MEDICINE, 2016, 95 (26)

[9] Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease [J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (07) : 1047 - 1047

[10] Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS) [J]. VACCINE, 2015, 33 (36) : 4398 - 4405